Overview

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A

Status:
Completed

Trial end date:
2018-12-12

Target enrollment:

Participant gender:

Summary

This trial is conducted in China. The aim of this trial is to evaluate the clinical efficacy of turoctocog alfa in treatment of bleeding episodes in Chinese patients with severe haemophilia A (FVIII≤1%).

Phase:

Phase 3

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Factor VIII